Please login to the form below

orphan medicines

This page shows the latest orphan medicines news and features for those working in and with pharma, biotech and healthcare.

NICE and Canadian counterpart to offer joint advice service

Just last month NICE, CADTH and The US-based Institute for Clinical and Economic Review (ICER) announced they will team up on a medicines cost evaluation project. ... orphan medicines.

Latest news

EMA sees approval numbers rise in 2018

From these, 21 were orphan medicines (exactly 50%) and three were advanced therapy medicinal products – Novartis’ Kymriah and Gilead/Kite’s Yescarta CAR-T therapies, plus Spark’s Luxturna, co-marketed ... Lastly, the EMA’s key human medicines
Beneluxa: the future of European market access?

However there is one specialist area in which there is unquestionably a growing appetite for European greater collaboration: health technology assessment of innovative medicines. ... and has so far focused on appraising high cost orphan medicines.
Orphan drugs from Biogen and Amicus win UK Prix Galien

There was a much warmer welcome at the awards, hosted by ValueBase, for the pharma and biotech companies with products on the shortlist, which was dominated by orphan medicines. ... All bar one of the finalists were medicines for orphan conditions, and
EMA forges closer ties with HTA umbrella group

The EMA has extended a partnership with the organisation representing Europe’s health technology assessment (HTA) bodies, aimed at improving access to medicines, for another three years. ... Other projects will look at how the regulator and HTAs define
The future of biotech

IMS data for 2015 highlighted that six out of ten of the world's best-selling medicines were biologics: $18bn for Harvoni, a new medicine; $15bn for Humira and $6bn for ... In the US there may be federal developments. In the UK it has led to fragmented

More from news
Approximately 2 fully matching, plus 40 partially matching documents found.

Latest Intelligence

Shoring up the framework

Consequently pharmaceutical companies that hold marketing authorisations for centrally authorised medicines will be required to take certain steps. ... Marketing authorisation holders for medicines, including orphan drugs, must be established in the EU
Brexit: Implications for the pharma industry

Similarly, orphan drug designations currently need to be held by an EU-based entity. ... If the UK ends up outside the EEA, it may, like other non-EEA countries, put in place reduced assessment processes for products categorised as orphan drugs by the
A rare talent

Shire’s Sebastian Stachowiak on dealing with change and working for a fit-for-purpose orphan drug environment. ... The latter, says Sebastian, is “a very good first step, in terms of recognising that there is a difference when it comes to
Market access improvements in Turkey

Almost the entire pharmaceutical market is made up of prescription medicines (93.8%) with 87% reimbursed. ... While welcoming the promise of a slight acceleration of review time with high priority medicines, industry is disappointed that orphan drugs and
Tracking comms trends: Europe in the global vanguard on value

For example, last year the three Benelux countries signed a statement of intent to jointly procure orphan medicines in an effort to lower prices. ... More locally, US HMOs and insurance funds are using levels of HTA and deploying cost containment